Rodney Paul Rocconi, MD University of South Alabama discusses A phase I combination study of GMCSF/bi-shRNA(furin) DNA-transfected autologous tumor immunotherapy and atezolizumab in recurrent/refractory advanced-stage ovarian cancer: Efficacy assessment in BRCA1/2-wt patients
ASCO